Other large drugmakers including Pfizer Inc PFE

About Mexico AliveMexico Alive represents some of the most reputable and established developers inthe Puerto Vallarta and Riviera Nayarit areas. With unique and exclusiveproperties such as Haixa, 3.14 Living, Marival, Delcanto, Las Lunas, El Cid andGrand Bahia Principe, Mexico Alive is able to meet the needs of a diverseclientele by providing quality investments coupled with superb customer service.Learn more at Mexico AliveRobin Noelle, 52 (322) Business Wire 2009. Three major needs thatKansas City GM Dayton Moore has, and a possible solution to all three: 1. Left-Handed StarterThe Royals need to insert a lefthander into the rotation to avoid having a one through five of all righthanders.

The free agent market is thin at lefties, but there are two intriguing options that KC could look at. Erik Bedard is the popular name being thrown around at the moment. If his price is too high, don't be surprised to see Doug Davis' name come up. Arizona declined to offer him arbitration, and he could come as an affordable No 4 starter. The only issue is that Davis' agent is saying they will be looking for a multi-year deal. The fact that Davis has never had an arm-related injury could put the 34 year old in range for a 2-3 year deal with $3.5-4 million per year. 2.

He was a Type-A free agent this offseason, but did not receive an offer of arbitration from Los Angeles. Coming off a career year, Oliver could be looking for a one-year contract in the ballpark of $3 million. A high price that needs to be paid to get the AL's worst bullpen back on track. 3. Everyday Starting CatcherThe constant switching between John Buck and Miguel Olivo isn't going to be tolerated another season. This may be the position that the Royals may need to open the checkbook Yorvit Torrealba is the ideal choice here. If Moore is serious about filling the question mark behind the plate, he'll have to bid up against the Dodgers and Giants for Torrealba. .

NEW YORK (Reuters) - The chief executive of Wyeth WYE.N said on Wednesday the U.S. drugmaker's strong cash position could enable it to make new biotech acquisitions despite competition from generic drugmakers for several of its biggest products. DealsBernard Poussot, speaking at a Goldman Sachs health-care meeting, noted that many of the company's top-selling products are biotech medicines large proteins made in living cells that are becoming a lucrative mainstay of treatment for a wide range of diseases.The global recession has caused valuations of many biotechs to shrink dramatically in the past year, making the tiny companies more tempting prey for large drugmakers.Poussot said Wyeth, with $14 billion in cash, is in good shape for acquiring "attractive technologies.""Our goal is to deliver reliable and sustainable growth over the years," he said. "To achieve that, our best strategy is to build one of the most global diversified biopharmaceutical companies."Other large drugmakers, including Pfizer Inc (PFE.N) and Merck & Co (MRK.N), have also said that falling prices of biotechs could make them riper for the picking.In the meantime, Poussot said Wyeth whose drugs tend to treat symptomatic illness seems to be more "recession-proof" than rival drugmakers whose products treat chronic ailments like high cholesterol or blood pressure that are often asymptomatic.Poussot also predicted that an improved form of Wyeth's blockbuster Prevnar vaccine to prevent infant and child infections with pneumococcal bacteria may be approved in the United States this year.The new product, called Prevnar 13, is designed to protect against 13 strains of the bacteria which cause ailments ranging from ear infections to pneumonia and confer greater protection than the current seven-strain vaccine.Wyeth plans to seek U.S. approval of Prevnar 13 by March, he said, for use in infants and young children. The company is also testing the new product in adults, a potential big new market for the Prevnar franchise.Wyeth earnings have been hurt by the unexpected launch early last year of a generic form of its Protonix ulcer medicine. Moreover, its $4 billion-a-year Effexor XR depression drug is now facing competition in Europe from cheaper generics and will lose patent protection by 2010 in the crucial U.S.